News Agency
The Times

IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing

  • Written by PR Newswire
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
  • IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment.
  • Maximum dose reached with no dose-limiting toxicities observed.
  • TLX101-Tx is also the subject of a pivotal trial, IPAX BrIGHT, which is actively dosing patients with recurrent glioblastoma.

MELBOURNE, Australia and INDIANAPOLIS, May 19, 2026 /PRNewswire/ --...

Read more: IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing

Why Businesses Rely On Accountants in Melbourne For Financial Success

Managing finances effectively is essential for individuals, business owners, investors, and growing organisations. Financial decisions influence profitability, compliance, cash flow, and long-term wealth creation, making professional financial guidance an important part of successful planning. Many individuals and businesses choose to... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion